Glenmark Receives USFDA EIR for Goa Facility With VAI Status
New Delhi: Glenmark Pharmaceuticals Ltd (Glenmark), a research-led, global pharmaceutical company has announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations manufacturing facility in Goa, India with a Voluntary Action Indicated (VAI) status.
The inspection was conducted at the Company’s manufacturing facility from June 22, 2026 to June 30, 2026.
Glenmark Pharmaceuticals' manufacturing facilities are spread across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries. It deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology.
